- Home
- CRBU vs LXEO Comparison
CRBU vs LXEO Comparison
Compare CRBU & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBU
- LXEO
- Stock Information
- Founded
- CRBU 2011
- LXEO 2017
- Country
- CRBU United States
- LXEO United States
- Employees
- CRBU N/A
- LXEO N/A
- Industry
- CRBU Medicinal Chemicals and Botanical Products
- LXEO
- Sector
- CRBU Health Care
- LXEO
- Exchange
- CRBU Nasdaq
- LXEO Nasdaq
- Market Cap
- CRBU 93.0M
- LXEO 93.9M
- IPO Year
- CRBU 2021
- LXEO 2023
- Fundamental
- Price
- CRBU $1.63
- LXEO $4.49
- Analyst Decision
- CRBU Strong Buy
- LXEO Strong Buy
- Analyst Count
- CRBU 4
- LXEO 5
- Target Price
- CRBU $8.50
- LXEO $16.60
- AVG Volume (30 Days)
- CRBU 1.9M
- LXEO 520.2K
- Earning Date
- CRBU 08-05-2025
- LXEO 08-11-2025
- Dividend Yield
- CRBU N/A
- LXEO N/A
- EPS Growth
- CRBU N/A
- LXEO N/A
- EPS
- CRBU N/A
- LXEO N/A
- Revenue
- CRBU $9,918,000.00
- LXEO N/A
- Revenue This Year
- CRBU $9.52
- LXEO N/A
- Revenue Next Year
- CRBU N/A
- LXEO N/A
- P/E Ratio
- CRBU N/A
- LXEO N/A
- Revenue Growth
- CRBU N/A
- LXEO N/A
- 52 Week Low
- CRBU $0.66
- LXEO $1.45
- 52 Week High
- CRBU $3.00
- LXEO $19.50
- Technical
- Relative Strength Index (RSI)
- CRBU 66.57
- LXEO 63.76
- Support Level
- CRBU $1.34
- LXEO $3.91
- Resistance Level
- CRBU $1.79
- LXEO $4.85
- Average True Range (ATR)
- CRBU 0.12
- LXEO 0.33
- MACD
- CRBU 0.03
- LXEO 0.02
- Stochastic Oscillator
- CRBU 72.84
- LXEO 78.69
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.